-
1
-
-
77949822338
-
-
Version 1, Available at: Accessed June 30, 2010
-
Zelenetz AD, Abramson JS, Advani RH, et al. NCCN clinical practice guidelines in oncology: non-Hodgkin's lymphomas. Version 1, 2010. Available at: http://www.nccn.org/professionals/physician-gls/PDF/nhl.pdf. Accessed June 30, 2010.
-
(2010)
NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphomas
-
-
Zelenetz, A.D.1
Abramson, J.S.2
Advani, R.H.3
-
2
-
-
1842413105
-
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
-
The Non-Hodgkin's Lymphoma Classification Project
-
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909-3918.
-
(1997)
Blood
, vol.89
, pp. 3909-3918
-
-
-
3
-
-
67650874081
-
Cancer statistics, 2009
-
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
-
(2009)
CA Cancer J Clin
, vol.59
, pp. 225-249
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
-
4
-
-
77958475528
-
-
Available at: Accessed May 3, 2010
-
Leukemia & Lymphoma Society. Facts 2009-2010. Available at: http://www.leukemia-lymphoma.org/attachments/National/br-1247234696.pdf. Accessed May 3, 2010.
-
Facts 2009-2010
-
-
-
5
-
-
38549100098
-
Is lymphoma occurring in the elderly the same disease?
-
Armitage JO. Is lymphoma occurring in the elderly the same disease? Leuk Lymphoma 2008;49:14-16.
-
(2008)
Leuk Lymphoma
, vol.49
, pp. 14-16
-
-
Armitage, J.O.1
-
6
-
-
84983373947
-
-
Version 3, Available at: Accessed June 30, 2010
-
Anderson KC, Alsina M, Bensinger W, et al. NCCN clinical practice guidelines in oncology: multiple myeloma. Version 3, 2010. Available at: http://www.nccn.org/professionals/physician-gls/PDF/myeloma.pdf. Accessed June 30, 2010.
-
(2010)
NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma
-
-
Anderson, K.C.1
Alsina, M.2
Bensinger, W.3
-
8
-
-
58149382688
-
Classification of lymphoid neoplasms: The microscope as a tool for disease discovery
-
Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood 2008;112:4384-4399.
-
(2008)
Blood
, vol.112
, pp. 4384-4399
-
-
Jaffe, E.S.1
Harris, N.L.2
Stein, H.3
Isaacson, P.G.4
-
9
-
-
77949453079
-
The 2008 WHO classification of lymphomas: Implications for clinical practice and translational research
-
Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009;113:523-531.
-
(2009)
Hematology Am Soc Hematol Educ Program
, vol.113
, pp. 523-531
-
-
Jaffe, E.S.1
-
10
-
-
48149103434
-
Non-MALT marginal zone lymphomas
-
Thieblemont C. Non-MALT marginal zone lymphomas. Ann Oncol 2008;19(Suppl 4):70-73.
-
(2008)
Ann Oncol
, vol.19
, Issue.SUPPL. 4
, pp. 70-73
-
-
Thieblemont, C.1
-
11
-
-
60849139137
-
Current treatment options for Waldenström macroglobulinemia
-
Vijay A, Gertz MA. Current treatment options for Waldenström macroglobulinemia. Clin Lymphoma Myeloma 2008;8:219-229.
-
(2008)
Clin Lymphoma Myeloma
, vol.8
, pp. 219-229
-
-
Vijay, A.1
Gertz, M.A.2
-
12
-
-
62449324950
-
Follicular lymphoma in the United States: First report of the national LymphoCare study
-
Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009;27:1202-1208.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1202-1208
-
-
Friedberg, J.W.1
Taylor, M.D.2
Cerhan, J.R.3
-
13
-
-
34249726129
-
How I treat indolent lymphoma
-
Gribben JG. How I treat indolent lymphoma. Blood 2007;109:4617-4626.
-
(2007)
Blood
, vol.109
, pp. 4617-4626
-
-
Gribben, J.G.1
-
14
-
-
77958482397
-
A phase III study of rituximab plus CVP versus CVP alone in patients with previously untreated advanced follicular lymphoma: Updated results with 53 months" median follow-up and analysis of outcomes according to baseline prognostic factors
-
In press
-
Marcus RE, Imrie K, Solal-Celigny P, et al. A phase III study of rituximab plus CVP versus CVP alone in patients with previously untreated advanced follicular lymphoma: updated results with 53 months" median follow-up and analysis of outcomes according to baseline prognostic factors. J Clin Oncol, In press.
-
J Clin Oncol
-
-
Marcus, R.E.1
Imrie, K.2
Solal-Celigny, P.3
-
15
-
-
28544435078
-
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
-
Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-3732.
-
(2005)
Blood
, vol.106
, pp. 3725-3732
-
-
Hiddemann, W.1
Kneba, M.2
Dreyling, M.3
-
16
-
-
34249704600
-
Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: A systematic review and meta-analysis
-
Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706-714.
-
(2007)
J Natl Cancer Inst
, vol.99
, pp. 706-714
-
-
Schulz, H.1
Bohlius, J.F.2
Trelle, S.3
-
17
-
-
0033968522
-
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
-
Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000;18:317-324.
-
(2000)
J Clin Oncol
, vol.18
, pp. 317-324
-
-
Foran, J.M.1
Rohatiner, A.Z.2
Cunningham, D.3
-
18
-
-
0034999927
-
CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia
-
Treon SP, Agus DB, Link B, et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother (1991) 2001;24:272-279.
-
(2001)
J Immunother (1991)
, vol.24
, pp. 272-279
-
-
Treon, S.P.1
Agus, D.B.2
Link, B.3
-
19
-
-
23044510136
-
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
-
DOI 10.1200/JCO.2005.12.051
-
Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-4088. (Pubitemid 46211313)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.18
, pp. 4079-4088
-
-
Keating, M.J.1
O'Brien, S.2
Albitar, M.3
Lerner, S.4
Plunkett, W.5
Giles, F.6
Andreeff, M.7
Cortes, J.8
Faderl, S.9
Thomas, D.10
Koller, C.11
Wierda, W.12
Detry, M.A.13
Lynn, A.14
Kantarjian, H.15
-
20
-
-
19944429446
-
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
-
DOI 10.1182/blood-2004-03-0796
-
Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53. (Pubitemid 40053062)
-
(2005)
Blood
, vol.105
, Issue.1
, pp. 49-53
-
-
Byrd, J.C.1
Rai, K.2
Peterson, B.L.3
Appelbaum, F.R.4
Morrison, V.A.5
Kolitz, J.E.6
Shepherd, L.7
Hines, J.D.8
Schiffer, C.A.9
Larson, R.A.10
-
21
-
-
77958510526
-
First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a randomized phase III trial on behalf of an international group of investigators and the German CLL study group
-
abstract. Presented at the Abstract 535
-
Hallek MS, Fingerle-Rowson G, Fink AM, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL study group [abstract]. Presented at the 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana. Abstract 535.
-
51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana
-
-
Hallek, M.S.1
Fingerle-Rowson, G.2
Fink, A.M.3
-
22
-
-
33749545033
-
Rituximab maintenance improves clinical outcome of relapsed/refractory follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: Results of a prospective randomized phase 3 intergroup trial
-
van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/refractory follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295-3301.
-
(2006)
Blood
, vol.108
, pp. 3295-3301
-
-
Van Oers, M.H.1
Klasa, R.2
Marcus, R.E.3
-
23
-
-
33845515497
-
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
-
Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006;108:4003-4008.
-
(2006)
Blood
, vol.108
, pp. 4003-4008
-
-
Forstpointner, R.1
Unterhalt, M.2
Dreyling, M.3
-
24
-
-
60949107711
-
Rituximab maintenance for the treatment of patients with follicular lymphoma: Systematic review and meta-analysis of randomized trials
-
Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009;101:248-255.
-
(2009)
J Natl Cancer Inst
, vol.101
, pp. 248-255
-
-
Vidal, L.1
Gafter-Gvili, A.2
Leibovici, L.3
-
25
-
-
77958474816
-
Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy
-
abstract Presented at the Abstract 8004
-
Salles GA, Seymour JF, Feugier P, et al. Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy [abstract]. Presented at the 2010 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2010; Chicago, Illinois. Abstract 8004.
-
2010 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2010; Chicago, Illinois
-
-
Salles, G.A.1
Seymour, J.F.2
Feugier, P.3
-
26
-
-
77958468955
-
Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: Results of the PRIMA study
-
abstract. Presented at the Abstract 0557
-
Salles G, Catalano J, Feugier P, et al. Rituximab maintenance for 2-years significantly improves the outcome of patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy: results of the PRIMA study [abstract]. Presented at the 2010 Annual Meeting of the European Hematology Association; June 10-13, 2010; Barcelona, Spain. Abstract 0557.
-
2010 Annual Meeting of the European Hematology Association; June 10-13, 2010; Barcelona, Spain
-
-
Salles, G.1
Catalano, J.2
Feugier, P.3
-
27
-
-
77958503092
-
Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy
-
abstract. Presented at the Abstract 8005
-
Pettengell R, Schmitz N, Gisselbrecht C, et al. Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy [abstract]. Presented at the 2010 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2010; Chicago, Illinois. Abstract 8005.
-
2010 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2010; Chicago, Illinois
-
-
Pettengell, R.1
Schmitz, N.2
Gisselbrecht, C.3
-
28
-
-
75349085058
-
Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: A review of the evidence
-
Morschhauser F, Dreyling M, Rohatiner A, et al. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence. Oncologist 2009;14(Suppl 2):17-29.
-
(2009)
Oncologist
, vol.14
, Issue.SUPPL. 2
, pp. 17-29
-
-
Morschhauser, F.1
Dreyling, M.2
Rohatiner, A.3
-
29
-
-
55949118446
-
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma
-
Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156-5164.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5156-5164
-
-
Morschhauser, F.1
Radford, J.2
Van Hoof, A.3
-
30
-
-
33748671762
-
Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: Five-year follow-up of Southwest Oncology Group protocol S9911
-
Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group protocol S9911. J Clin Oncol 2006;24:4143-4149.
-
(2006)
J Clin Oncol
, vol.24
, pp. 4143-4149
-
-
Press, O.W.1
Unger, J.M.2
Braziel, R.M.3
-
32
-
-
77958464924
-
-
ClinicalTrials.gov Available at: Accessed March 31, 2010
-
ClinicalTrials.gov. Iodine I 131 tositumomab, rituximab, and combination chemotherapy in treating patients with previously untreated stage II, stage III, or stage IV follicular non-Hodgkin lymphoma. Available at: http:// clinicaltrials.gov/ct2/show/NCT00770224. Accessed March 31, 2010.
-
Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Patients with Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
-
-
-
33
-
-
12944275472
-
131I-tositumomab therapy as initial treatment for follicular lymphoma
-
DOI 10.1056/NEJMoa041511
-
Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441-449. (Pubitemid 40175970)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.5
, pp. 441-449
-
-
Kaminski, M.S.1
Tuck, M.2
Estes, J.3
Kolstad, A.4
Ross, C.W.5
Zasadny, K.6
Regan, D.7
Kison, P.8
Fisher, S.9
Kroll, S.10
Wahl, R.L.11
-
34
-
-
77958463097
-
Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage, follicular lymphoma: Median 10 year follow-up results
-
abstract. Presented at the Abstract 3759
-
Kaminski MS, Tuck M, Estes J, et al. Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage, follicular lymphoma: median 10 year follow-up results [abstract]. Presented at the 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana. Abstract 3759.
-
51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana
-
-
Kaminski, M.S.1
Tuck, M.2
Estes, J.3
-
35
-
-
33947541773
-
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US intergroup trial E2997
-
DOI 10.1200/JCO.2006.08.0762
-
Flinn IW, Neuberg DS, Grever MR, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup trial E2997. J Clin Oncol 2007;25:793-798. (Pubitemid 350002879)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.7
, pp. 793-798
-
-
Flinn, I.W.1
Neuberg, D.S.2
Grever, M.R.3
Dewald, G.W.4
Bennett, J.M.5
Paietta, E.M.6
Hussein, M.A.7
Appelbaum, F.R.8
Larson, R.A.9
Moore Jr., D.F.10
Tallman, M.S.11
-
36
-
-
34447530283
-
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): A randomised controlled trial
-
UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group
-
Catovsky D, Richards S, Matutes E, et al. UK National Cancer Research Institute (NCRI) Haematological Oncology Clinical Studies Group; NCRI Chronic Lymphocytic Leukaemia Working Group. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet 2007;370:230-239.
-
(2007)
Lancet
, vol.370
, pp. 230-239
-
-
Catovsky, D.1
Richards, S.2
Matutes, E.3
-
37
-
-
33947544426
-
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup phase III trial E2997
-
Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup phase III trial E2997. J Clin Oncol 2007;25:799-804.
-
(2007)
J Clin Oncol
, vol.25
, pp. 799-804
-
-
Grever, M.R.1
Lucas, D.M.2
Dewald, G.W.3
-
38
-
-
0037220152
-
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712)
-
Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6-14.
-
(2003)
Blood
, vol.101
, pp. 6-14
-
-
Byrd, J.C.1
Peterson, B.L.2
Morrison, V.A.3
-
39
-
-
19944429446
-
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011
-
DOI 10.1182/blood-2004-03-0796
-
Byrd JC, Rai K, Peterson BL, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53. (Pubitemid 40053062)
-
(2005)
Blood
, vol.105
, Issue.1
, pp. 49-53
-
-
Byrd, J.C.1
Rai, K.2
Peterson, B.L.3
Appelbaum, F.R.4
Morrison, V.A.5
Kolitz, J.E.6
Shepherd, L.7
Hines, J.D.8
Schiffer, C.A.9
Larson, R.A.10
-
40
-
-
23044510136
-
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
-
Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-4088.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4079-4088
-
-
Keating, M.J.1
O'Brien, S.2
Albitar, M.3
-
41
-
-
23044501404
-
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
-
DOI 10.1200/JCO.2005.12.516
-
Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005;23:4070-4078. (Pubitemid 46211312)
-
(2005)
Journal of Clinical Oncology
, vol.23
, Issue.18
, pp. 4070-4078
-
-
Wierda, W.1
O'Brien, S.2
Wen, S.3
Faderl, S.4
Garcia-Manero, G.5
Thomas, D.6
Do, K.-A.7
Cortes, J.8
Koller, C.9
Beran, M.10
Ferrajoli, A.11
Giles, F.12
Lerner, S.13
Albitar, M.14
Kantarjian, H.15
Keating, M.16
-
42
-
-
70350490537
-
How I treat Waldenström macroglobulinemia
-
Treon SP. How I treat Waldenström macroglobulinemia. Blood 2009;114:2375-2385.
-
(2009)
Blood
, vol.114
, pp. 2375-2385
-
-
Treon, S.P.1
-
43
-
-
65549105193
-
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
-
Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood 2009;113:3673-3678.
-
(2009)
Blood
, vol.113
, pp. 3673-3678
-
-
Treon, S.P.1
Branagan, A.R.2
Ioakimidis, L.3
-
44
-
-
77950464935
-
Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia
-
Ghobrial IM, Gertz M, Laplant B, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1408-1414.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1408-1414
-
-
Ghobrial, I.M.1
Gertz, M.2
Laplant, B.3
-
45
-
-
77950487663
-
Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia
-
Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1422-1428.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1422-1428
-
-
Ghobrial, I.M.1
Hong, F.2
Padmanabhan, S.3
-
46
-
-
40749085662
-
Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents
-
DOI 10.1158/1078-0432.CCR-07-1061
-
Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14:309-317. (Pubitemid 351378007)
-
(2008)
Clinical Cancer Research
, vol.14
, Issue.1
, pp. 309-317
-
-
Leoni, L.M.1
Bailey, B.2
Reifert, J.3
Bendall, H.H.4
Zeller, R.W.5
Corbeil, J.6
Elliott, G.7
Niemeyer, C.C.8
-
47
-
-
63049113411
-
Bendamustine: Rebirth of an old drug
-
Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009;27:1492-1501.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1492-1501
-
-
Cheson, B.D.1
Rummel, M.J.2
-
48
-
-
77958486743
-
Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: Final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany)
-
abstract Presented at the Abstract 405
-
Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany) [abstract]. Presented at the 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana. Abstract 405.
-
51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana
-
-
Rummel, M.J.1
Niederle, N.2
Maschmeyer, G.3
-
49
-
-
70349330220
-
Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia
-
Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378-4384.
-
(2009)
J Clin Oncol
, vol.27
, pp. 4378-4384
-
-
Knauf, W.U.1
Lissichkov, T.2
Aldaoud, A.3
-
50
-
-
77749258123
-
Clinical Roundtable monograph: Recent advances in NHL
-
Highlights from the 51st ASH Annual Meeting and Exposition, December 5-8, 2009, New Orleans, Louisiana
-
Czuczman MS, Rummel MJ. Clinical Roundtable monograph: recent advances in NHL. Highlights from the 51st ASH Annual Meeting and Exposition, December 5-8, 2009, New Orleans, Louisiana. Clin Adv Hematol Oncol 2010;8:A1-11.
-
(2010)
Clin Adv Hematol Oncol
, vol.8
-
-
Czuczman, M.S.1
Rummel, M.J.2
-
51
-
-
77958507260
-
Bendamustine-rituximab combination treatment in relapsed NHL: Combined experience from two phase 2 trials and exploration of response predictors
-
abstract Presented at the Abstract 0294
-
Kennedy D, Mwamburi M, Ranganathan G, et al. Bendamustine-rituximab combination treatment in relapsed NHL: combined experience from two phase 2 trials and exploration of response predictors [abstract]. Presented at the 2010 Annual Meeting of the European Hematology Association; June 10-13, 2010; Barcelona, Spain. Abstract 0294.
-
2010 Annual Meeting of the European Hematology Association; June 10-13, 2010; Barcelona, Spain
-
-
Kennedy, D.1
Mwamburi, M.2
Ranganathan, G.3
-
52
-
-
77958515159
-
Peripheral blood stem cell mobilization after bendamustine containing chemotherapy in indolent lymphomas is possible. Results from the phase III study of B-R vs. CHOP-R (NHL 1-2003 trial) of the StiL (Study group Indolent Lymphomas, Germany)
-
abstract Presented at the Abstract 2679
-
Burchardt CA, Brugger W, Maschmeyer G, et al. Peripheral blood stem cell mobilization after bendamustine containing chemotherapy in indolent lymphomas is possible. Results from the phase III study of B-R vs. CHOP-R (NHL 1-2003 trial) of the StiL (Study group Indolent Lymphomas, Germany) [abstract]. Presented at the 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana. Abstract 2679.
-
51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana
-
-
Burchardt, C.A.1
Brugger, W.2
Maschmeyer, G.3
-
53
-
-
73949145763
-
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma
-
Witzig TE, Wiernik PH, Moore T, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 2009;27:5404-5409.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5404-5409
-
-
Witzig, T.E.1
Wiernik, P.H.2
Moore, T.3
-
54
-
-
77958468863
-
A biologic combination of lenalidomide and rituximab for front-line therapy of indolent B-cell non-Hodgkin's lymphoma
-
abstract Abstract 1714
-
Fowler N, McLaughlin P, Hagemeister FB, et al. A biologic combination of lenalidomide and rituximab for front-line therapy of indolent B-cell non-Hodgkin's lymphoma [abstract]. Program and abstracts of the 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana. Abstract 1714.
-
Program and Abstracts of the 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana
-
-
Fowler, N.1
McLaughlin, P.2
Hagemeister, F.B.3
-
55
-
-
77958496772
-
Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma
-
abstract. Presented at the Abstract 8036
-
Fowler NH, McLaughlin P, Hagemeister FB, et al. Complete response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin's lymphoma (abstract). Presented at the 2010 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2010; Chicago, Illinois. Abstract 8036.
-
2010 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2010; Chicago, Illinois
-
-
Fowler, N.H.1
McLaughlin, P.2
Hagemeister, F.B.3
-
56
-
-
77958512183
-
R2: Preliminary results of a phase II study of lenalidomide and rituximab in relapsed/refractory indolent non-Hodgkin's lymphoma (NHL)
-
abstract. Presented at the Abstract 1679
-
Dutia M, DeRoock I, Chee K, et al. R2: preliminary results of a phase II study of lenalidomide and rituximab in relapsed/refractory indolent non-Hodgkin's lymphoma (NHL) [abstract]. Presented at the 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana. Abstract 1679.
-
51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana
-
-
Dutia, M.1
DeRoock, I.2
Chee, K.3
-
57
-
-
77958467908
-
Analysis of a phase 2 study of lenalidomide and rituximab in relapsed or refractory non-Hodgkin's lymphoma
-
abstract Abstract 0295
-
Dutia M, DeRoock I, Chee K, et al. Analysis of a phase 2 study of lenalidomide and rituximab in relapsed or refractory non-Hodgkin's lymphoma [abstract]. Program and abstracts of the 2010 Annual Meeting of the European Hematology Association; June 10-13, 2010; Barcelona, Spain. Abstract 0295.
-
Program and Abstracts of the 2010 Annual Meeting of the European Hematology Association; June 10-13, 2010; Barcelona, Spain
-
-
Dutia, M.1
DeRoock, I.2
Chee, K.3
-
58
-
-
74949083498
-
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics
-
Sher T, Miller KC, Lawrence D, et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma 2010;51:85-88.
-
(2010)
Leuk Lymphoma
, vol.51
, pp. 85-88
-
-
Sher, T.1
Miller, K.C.2
Lawrence, D.3
-
59
-
-
77958486445
-
Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: Encouraging activity in the phase 2 VERTICAL study
-
abstract Presented at the Abstract 933
-
Fowler N, Kahl BS, Rosen P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: encouraging activity in the phase 2 VERTICAL study [abstract]. Presented at the 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana. Abstract 933.
-
51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana
-
-
Fowler, N.1
Kahl, B.S.2
Rosen, P.3
-
60
-
-
68949135695
-
Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180
-
Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009;27:3830-3835.
-
(2009)
J Clin Oncol
, vol.27
, pp. 3830-3835
-
-
Treon, S.P.1
Ioakimidis, L.2
Soumerai, J.D.3
-
61
-
-
77958516236
-
Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma
-
abstractPresented at the Abstract 935
-
Hagenbeek A, Fayad L, Delwail V, et al. Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma [abstract]. Presented at the 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana. Abstract 935.
-
51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, Louisiana
-
-
Hagenbeek, A.1
Fayad, L.2
Delwail, V.3
-
62
-
-
77958463096
-
Ofatumumab in combination with chop (O-CHOP) achieves high response rates in previously untreated follicular lymphoma (FL) patients with high-risk FLIPI scores
-
abstract Presented at the Abstract 0237
-
Czuczman S, Viardot A, Hess G, et al. Ofatumumab in combination with chop (O-CHOP) achieves high response rates in previously untreated follicular lymphoma (FL) patients with high-risk FLIPI scores [abstract]. Presented at the 2010 Annual Meeting of the European Hematology Association; June 10-13, 2010; Barcelona, Spain. Abstract 0237.
-
2010 Annual Meeting of the European Hematology Association; June 10-13, 2010; Barcelona, Spain
-
-
Czuczman, S.1
Viardot, A.2
Hess, G.3
-
64
-
-
77958497722
-
Promising efficacy with the new anti-cd20 antibody ga101 in heavily pre-treated patients - First results from a phase II study in patients with relapsed/refractory indolent NHL (INHL)
-
abstract Presented at the Abstract 0558
-
Salles A, Morschhauser F, Thieblemont C, et al. promising efficacy with the new anti-cd20 antibody ga101 in heavily pre-treated patients - first results from a phase II study in patients with relapsed/refractory indolent NHL (INHL) [abstract]. Presented at the 2010 Annual Meeting of the European Hematology Association; June 10-13, 2010; Barcelona, Spain. Abstract 0558.
-
2010 Annual Meeting of the European Hematology Association; June 10-13, 2010; Barcelona, Spain
-
-
Salles, A.1
Morschhauser, F.2
Thieblemont, C.3
-
65
-
-
77951002653
-
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
-
Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-2585.
-
(2010)
Blood
, vol.115
, pp. 2578-2585
-
-
Friedberg, J.W.1
Sharman, J.2
Sweetenham, J.3
|